dc.contributor.author | Uludağ, Damla | |
dc.contributor.author | Karakaş, Nihal | |
dc.date.accessioned | 2021-08-02T11:44:09Z | |
dc.date.available | 2021-08-02T11:44:09Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Uludağ, D. ve Karakaş, N. (2021). IL13 fused pseudomonas exotoxin targets various cancers in vitro. Anticancer Research, 41(7), 3471-3480. https://dx.doi.org/10.21873/anticanres.15134 | en_US |
dc.identifier.issn | 0250-7005 | |
dc.identifier.issn | 1791-7530 | |
dc.identifier.uri | https://dx.doi.org/10.21873/anticanres.15134 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/7646 | |
dc.description.abstract | Background/Aim: Pseudomonas exotoxin (PE) is one of the most widely used toxins in the construction of therapeutic fusion proteins in pre-clinical studies followed by phase trials. In principle, PE acts by blocking protein synthesis through catalyzing the inactivation of elongation factor-2 (EF-2). The interleukin-13 fused PE (IL13-PE) cytotoxin was previously designed to target GBM cells. In this study, the cytotoxic effects of IL13-PE were evaluated in 5 different types of cancers and the therapeutic effects were further analyzed in a lung cancer cell line, NCI-H460. Conceptually, in another lung cancer cell line (A549), ILI 3R alpha 2 was overexpressed by lentiviruses (A549-IL13R alpha 2) and evaluated for cytotoxic efficacy of IL13-PE. Materials and Methods: The expression profile of IL13R alpha 2 in different cancer cell lines was determined by RT-PCR. Secretable toxin fusion was expressed in the toxin resistant HEK-293T cell line (293T-TxR) by using a plasmid coding for IL13-PE and IRESGFP (LV-IL13-PE-IRESIGFP). Next, the cells were shown to produce and secrete functional ILI3-PE by dot blot analysis, followed by cell viability assays and cell death analysis. Results: Upon treatment with IL13-PE, a significant decrease in cell viability was selectively demonstrated in cancer cells with cognate receptor expression. IL13-PE treatment increased the apoptoticlnecrotic cell populations in the NCIH460 cell line. Conclusion: Our results demonstrate that IL13-PE can be a therapeutic target for tumors bearing mostly IL13R alpha 2 positive cell populations. Our findings also suggest a cell-based delivery option for the recombinant toxins in the treatment of different cancers which can provide a solution for the clinical use of toxin therapy. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | International Institute of Anticancer Research | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Cancer | en_US |
dc.subject | IL13 | en_US |
dc.subject | IL13Rα2 | en_US |
dc.subject | Pseudomonas Exotoxin | en_US |
dc.subject | Recombinant Toxin | en_US |
dc.subject | Toxin | en_US |
dc.title | IL13 fused pseudomonas exotoxin targets various cancers in vitro | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Anticancer Research | en_US |
dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü | en_US |
dc.department | İstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji ve Genetik Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-9096-1512 | en_US |
dc.identifier.volume | 41 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.startpage | 3471 | en_US |
dc.identifier.endpage | 3480 | en_US |
dc.relation.tubitak | info:eu-repo/grantAgreement/TUBITAK/SOBAG/117S421 | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.21873/anticanres.15134 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q2 | en_US |